2012-12-31  A U.S. Appeals Court ruling that pitted free speech rights versus off-label promotion of pharmaceuticals has raised speculation that 2013 may usher in the sort of aggressive marketing by drug makers that

2012-10-05  The first trial in which evidence was taken in the mass tort litigation over Risperdal, the antipsychotic drug that plaintiffs have claimed causes males to grow breasts, was settled as part of

2012-10-04  Sheller attorneys announce that five Risperdal cases have been settled for confidential amounts. “Our clients are very pleased,” Steve Sheller, a plaintiffs’ attorney, said in a Bloomberg report after the settlement was

Philadelphia Inquirer 2012-09-28 Public companies file documents with the U.S. Securities and Exchange Commission all the time, and the chief executive officer signs them to say they are true. Shareholders and others can

Bloomberg BusinessWeek 2012-09-10 – Johnson & Johnson (JNJ) settled a lawsuit on the first day of a trial over claims its antipsychotic drug Risperdal caused a male plaintiff to grow breast tissue, one of his

2012-07-02 –  “Fighting for What’s Right”Stephen Sheller decided more than three decades ago to be a champion for people who have been hurt, victimized or otherwise had their rights trampled upon. His dedication

Pharma Gossip Blog/The Philadelphia Inquirer 2012-06-14 – “The problem with sentencing a corporation is that is has no soul to damn nor body to kick” ~ U.S. District Judge Douglas P. Woodlock referencing a 19th century

2012-06-05 –  Again this year, Jamie Sheller was a speaker at the Annual HB Litigation Conference NetDiligence Cyber Risk & Privacy Liability Forum. The forum took place June 4 and 5, 2012 at

Continuing Legal Education Programs 2012-05-22 – Attorney Jamie Sheller presented at the May Pennsylvania Bar Institute continuing legal education program “How to Properly Document a Settlement Agreement: After the New Joint and Several Liability

Insider Exclusive Television Documentaries 2012-05-18 “Deadly Drugs: Johnson and Johnson’s Risperdal” examines the evolution of the drug Risperdal® from treatment of schizophrenia and extreme bipolar mania to off-label use in children and the